In both the univariate analysis and the multivariate model, the use of DPP4 inhibitors was significantly associated with an increased risk of developing ARDS (OR = 1.945, 95% CI: 1.189–3.183, p = 0.008; adj. Here, DPP4 is linked to acute respiratory distress syndrome.